Sydney Stewart, Author at BioTuesdays

Developments

GlycoMimetics planning proof-of-concept trial for anti-tumor candidate

GlycoMimetics (NASDAQ:GLYC) plans to test GMI-1359, a dual function antagonist, in breast cancer patients whose tumors have spread to bone. GMI-1359 targets both E-selectin and CXCR4, which are involved in tumor...

April 12, 2019

Developments

Otonomy starts Phase 1/2 trial of OTO-313 for tinnitus

Otonomy (NASDAQ:OTIC) initiated a Phase 1/2 trial of OTO-313, a novel formulation of gacyclidine, for the treatment of tinnitus. Patients with tinnitus experience noise or ringing in their ears. Otonomy notes that some...

April 11, 2019

Developments

PhaseBio Pharma granted FDA breakthrough designation for antiplatelet reversal drug

PhaseBio Pharmaceuticals (NASDAQ:PHAS) received the FDA’s breakthrough therapy designation for PB2452, a drug designed to reverse the effects of antiplatelet drug, ticagrelor. Ticagrelor is administered to patients to...

April 9, 2019

Developments

IntelGenx receives positive feedback for Montelukast VersaFilm at ADPD conference

IntelGenx’s (TSX-V:IGX) (OTCQX:IGXT) Montelukast VersaFilm program received positive and constructive feedback from the scientific community at the 14thInternational Conference on Alzheimer’s & Parkinson’s Diseases...

April 8, 2019

Developments

Profound Medical posts positive top line pivotal trial results in prostate cancer with TULSA-PRO

Profound Medical (TSX:PRN; OTCQX:PRFMF) reported positive top line results from the TACT pivotal study designed to support its application to the FDA for 510(k) clearance to market TULSA-PRO in the U.S. The TULSA-PRO...

April 5, 2019

Developments

BriaCell immunotherapy/KEYTRUDA combination increases anti-tumor activity in early trial

BriaCell Therapeutics (TSX-V:BCT) (OTCQB:BCTXF) announced that early Phase 1/2a data suggest its Bria-IMT immunotherapy, combined with the checkpoint inhibitor KEYTRUDA, demonstrated additive or synergistic anti-tumor...

April 3, 2019

Developments

Evogene to develop next generation medical cannabis products

Evogene (NASDAQ, TASE:EVGN) has established a new subsidiary, Canonic, to develop next generation medical cannabis products. Evogene has been evaluating the medical cannabis field for more than a year, including market...

April 3, 2019

Developments

Imagin Medical successfully completes i/Blue functional unit assembly

Imagin Medical (CSE:IME; OTCQB:IMEXF; Frankfurt & Stuttgart: DPD2) has completed assembly of its i/Blue Imaging System’s functional unit, which has met the company’s pre-established performance expectations. The...

April 2, 2019

Developments

Supernus Pharma again posts positive Phase 3 ADHD data

Supernus Pharma (NASDAQ:SUPN) announced top-line results from P304, its Phase 3 study of SPN-812 in adolescents with attention deficit hyperactivity disorder (ADHD). SPN-812 is a non-stimulant serotonin norepinephrine...

March 29, 2019

Developments

BeyondSpring to present promising new strategy for cancer treatment with Plinabulin

BeyondSpring (NASDAQ: BYSI) will present a promising new strategy for cancer treatment involving the ability of its lead asset, Plinabulin, to positively shift the balance of macrophage phenotypes for a beneficial anti...

March 26, 2019

Author - Sydney Stewart

GlycoMimetics planning proof-of-concept trial for anti-tumor candidate

Otonomy starts Phase 1/2 trial of OTO-313 for tinnitus

PhaseBio Pharma granted FDA breakthrough designation for antiplatelet reversal drug

IntelGenx receives positive feedback for Montelukast VersaFilm at ADPD conference

Profound Medical posts positive top line pivotal trial results in prostate cancer with TULSA-PRO

BriaCell immunotherapy/KEYTRUDA combination increases anti-tumor activity in early trial

Evogene to develop next generation medical cannabis products

Imagin Medical successfully completes i/Blue functional unit assembly

Supernus Pharma again posts positive Phase 3 ADHD data

BeyondSpring to present promising new strategy for cancer treatment with Plinabulin

Subscribe